Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 2/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 2/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18174546 | 0.92 | ALB (0.49) | ALBSIRT5TLR2NOD1ROCK2 | |
| SCHEMBL24461841 | 0.92 | ALB (0.49) | ALBSIRT5TLR2NOD1ROCK2 | |
| SCHEMBL12227120 | 0.87 | NOD1 (0.44) | ALBSIRT5TLR2NOD1NMT2 | |
| SCHEMBL21305215 | 0.85 | ALB (0.44) | ALBSIRT5TLR2NOD1ROCK2 | |
| SCHEMBL14902998 | 0.81 | CASP2 (0.51) | ALBSIRT5TLR2NOD1EPHX2 | |
| SCHEMBL25129549 | 0.80 | NOD1 (0.39) | ALBNOD1NMT2NMT1EPHX2 | |
| SCHEMBL10027319 | 0.80 | MEN1 (0.52) | ALBSIRT5TLR2NOD1ROCK2 | |
| SCHEMBL25129822 | 0.79 | NMT2 (0.44) | TLR2NOD1NMT2NMT1GLP1R | |
| SCHEMBL10033607 | 0.78 | ALB (0.45) | ALBSIRT5TLR2NOD1NMT2 | |
| SCHEMBL10130532 | 0.78 | SIRT5 (0.60) | ALBSIRT5TLR2NOD1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027739-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | ENTRADA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022271818-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | ENTRADA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220033787-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY | ENTRADA THERAPEUTICS, INC. | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033787-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY | PYGB, FPGS, GLS2 | ALB 2187/4885SIRT5 3403/4885TLR2 4268/4885 |
| US-20230027739-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | PRCP, TAP1, DNPEP | ALB 2732/4885SIRT5 4627/4885TLR2 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.